The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
HypertensionMetabolic Syndrome
Interventions
DRUG

Aliskerin/Valsartan and Rampiril

"Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of \< 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)"

Trial Locations (1)

48106

University of Michigan Health System, Ann Arbor

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Michigan

OTHER